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It is our hope that this document will serve several useful
purposes. Our primary goal is to improve patient care. We hope
to accomplish this, in the short term, by helping clinicians
know and better understand the evidence (or lack of evidence)
that determines current practice. By providing comprehensive
evidence-based recommendations, this guideline will also help
define areas where evidence is lacking and research is needed.
Helping to define a research agenda is an often neglected, but very
important, function of clinical practice guideline development.
We used the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) system to rate the
quality of evidence and the strength of recommendations. In
all, there were no recommendations in this guideline for which
the overall quality of evidence was graded ‘A,’ whereas
4 (23.5%) were graded ‘B,’ 3 (17.7%) were graded ‘C,’ and
10 (58.8%) were graded ‘D.’ Although there are reasons other
than quality of evidence that underpin a grade 1 or 2 recomm-
endation, in general, there is a correlation between the quality
of overall evidence and the strength of the recommendation.
Thus, there were 8 (47.1%) recommendations graded ‘1’ and 9
(52.9%) graded ‘2.’ There were no recommendations graded
‘1A,’ 4 (23.5%) were ‘1B,’ 2 (11.8%) were ‘1C,’ and 2 (11.8%)
were ‘1D.’ There were no recommendations graded ‘2A’ or ‘2B,’
1 (5.9%) was ‘2C,’ and 8 (47.1%) were ‘2D.’ There were
4 (19.1%) statements that were not graded.
Some argue that recommendations should not be made
when evidence is weak. However, clinicians still need to make
decisions in their daily practice, and they often ask, ‘What do
the experts do in this setting?’ We opted to give guidance,
rather than remain silent. These recommendations are often
rated with a low strength of recommendation and a low
quality of evidence, or were not graded. It is important for
the users of this guideline to be cognizant of this (see Notice).
In every case these recommendations are meant to be a place
for clinicians to start, not stop, their inquiries into specific
management questions pertinent to the patients they see in
daily practice.
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